



LIBRARIES
UNIVERSITY OF WISCONSIN - MADISON

Temgesic advertisement.

[s.l.]: [s.n.], 1977

<https://digital.library.wisc.edu/1711.dl/7WHJN4FSCXW3U83>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.

Prescribing Information

Temgesic Injection 0.3mg/ml buprenorphine, as the hydrochloride, ampoules of 1ml (0.3mg) or 2ml (0.6mg).
Temgesic Sublingual tablet containing 0.2mg buprenorphine, as the hydrochloride. **Uses:** As a strong analgesic for the relief of moderate to severe pain. **Dosage and Administration:**
Temgesic Injection: Adults: 1-2ml (0.3-0.6mg) by i.m. or slow i.v. injection, every six to eight hours or as required.
Temgesic Sublingual: 1-2 tablets (0.2-0.4mg buprenorphine) dissolved under the tongue, every 6 to 8 hours or as required. The tablet should not be chewed or swallowed.
Temgesic is not at present recommended for children.


Contra-Indications, Warnings, etc: There are no absolute contra-indications for Temgesic. However, care should be taken when treating patients with impaired respiratory function as Temgesic may infrequently affect

respiration. Because buprenorphine has antagonist properties, it may precipitate mild withdrawal symptoms in narcotic addicts, and it should be given with care initially to patients previously treated with narcotic analgesics. Temgesic may cause some drowsiness; this could be potentiated by other centrally-acting agents, including alcohol. Ambulant patients should be warned not to drive or operate machinery if affected. Since buprenorphine is metabolised in the liver, the intensity and duration of its

action may be affected in patients with impaired liver function. Until further information is available, Temgesic should be used with caution in patients receiving monoamine oxidase inhibitors, and it is not recommended for use during pregnancy. **Side Effects:** Drowsiness is the most common side effect. In common with other strong analgesics, nausea, vomiting, dizziness and sweating have been reported and may be more frequent in ambulant patients. Clinically significant respiratory depression has been observed rarely and only in the post-operative period. **Product Licence Numbers,**



NHS Price: at January 1982. Temgesic injection 1ml - 44/0056. £5.52/pack 10 ampoules. Temgesic injection 2ml - 44/0057. £9.89/pack 10 ampoules. Temgesic Sublingual PL44/0063. £6.00/pack 50 tablets. Irish Product Authorisation Nos. 1ml - PA27/3/1. 2ml - 27/3/2. Temgesic Sublingual No. PA27/3/3. Additional information available on request from: Reckitt & Colman Pharmaceutical Division, Hull HU8 7DS.



The Temgesic Post-operative Calendar

continuing relief from post-operative pain
with Temgesic Injection, followed by Temgesic Sublingual 6-8 hourly.



1 MON
2 TUES
3 WED
4 THUR
5 FRI
6 SAT
7 SUN

Temgesic[®]

buprenorphine hydrochloride

Injection

For the first few hours

Temgesic[®]

buprenorphine hydrochloride

Sublingual

For the next few days